MedTrace Logo

Exercise for Brain Health in the Fight Against Alzheimer's Disease

NCT03727360 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2026-05-01

Study results available
· View outcomes & findings →

Summary

The investigators aim to compare the effects of a 6-month moderate intensity exercise training (ET) intervention to a low intensity flexibility exercise control condition (FC) on brain function, cognition, and physical function in cognitively healthy and physically inactive older adults (ages 60-80). Apolipoprotein E epsilon4 (APOE-ε4) allele carriers are known to be at substantially greater risk for cognitive decline and Alzheimer's disease (AD). Cognitively intact APOE-ε4 allele carriers, and non-carriers, will be randomly assigned to 6-months of either supervised moderate intensity aerobic exercise training (ET) or supervised flexibility exercise control (FC). The ET and FC each contain a group based exercise component and are run in local retirement communities near College Park, MD, or on the University of Maryland College Park campus. The primary aims of the study are to compare pre-intervention to post-intervention changes in episodic memory performance and MRI biomarkers.

Conditions

  • Healthy Cognition

Interventions

OTHER

Exercise Training

Supervised exercise conducted four days per week for six months.

OTHER

Flexibility Control

Supervised exercise conducted four days per week for six months.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Johns Hopkins University

    collaborator OTHER

  • Marquette University

    collaborator OTHER

  • University of Maryland, Baltimore

    collaborator OTHER

  • University of Maryland, College Park

    lead OTHER

Principal Investigators

  • J. Carson Smith, PhD · University of Maryland

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-08
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03727360 on ClinicalTrials.gov